ALNY Alnylam Pharmaceuticals Loading...

From GILD earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
21:30
Feb 10 ◎
Daniel O'Day CEO, Gilead Sciences, Inc. GILD Q4 FY25 call
Gilead's BD focus could target RNAi or other modalities where Alnylam is a leader, though no specific deal mentioned.
ALNY
LOW

About ALNY Analyst Coverage

Buzzberg tracks ALNY (Alnylam Pharmaceuticals) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Daniel O'Day.